ActiveMSers Forums  

Go Back   ActiveMSers Forums > ActiveMSers.org Forums > General

Reply
 
Thread Tools Display Modes
  #1  
Old 11-15-2017, 03:11 PM
ActiveMSers's Avatar
ActiveMSers ActiveMSers is online now
Dave @ ActiveMSers
 
Join Date: Jun 2008
Location: Albuquerque, NM
Posts: 3,265
Default Low dose naltrexone (LDN) fails to impress in new review

Bart's MS take: LDN is a treatment tried by many but there is no clear evidence of whether it works. This study looked at the treatments taken after LDN and it was not reduced, so there is no evidence for LDN-induced benefit.

PLoS One. 2017 Nov 3;12(11):e0187423. doi: 10.1371/journal.pone.0187423. eCollection 2017.

Low dose naltrexone in multiple sclerosis: Effects on medication use. A quasi-experimental study.

Raknes G1,2, Småbrekke L3.


Abstract

Low dose naltrexone (LDN) has become a popular off-label therapy for multiple sclerosis (MS). A few small, randomized studies indicate that LDN may have beneficial effects in MS and other autoimmune diseases. If proven efficacious, it would be a cheap and safe alternative to the expensive treatments currently recommended for MS.

We investigated whether a sudden increase in LDN use in Norway in 2013 was followed by changes in dispensing of other medications used to treat MS. We performed a quasi-experimental before-and-after study based on population data from the Norwegian Prescription Database (NorPD). We included all patients that collected at least one LDN prescription in 2013, and had collected at least two medications with a reimbursement code for MS, or collected a medication with MS as the only indication in 2009 or 2010. Outcomes were differences in cumulative dispensed doses and incidence of users of disease modifying MS therapies, and medications used to treat MS symptoms two years before and two years after dispensing the initial LDN prescription.

The eligible 341 patients collected 20,921 prescriptions in the observation period. Apart from changes in line with general trends in MS therapy in Norway, there was no difference in neither dispensed cumulative doses or number of prevalent users of MS specific medication. Initiation of LDN was not followed by reductions of other medications used to treat symptoms associated with MS.

__________________
Dave Bexfield
ActiveMSers
Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump


All times are GMT -4. The time now is 05:51 AM.


Powered by vBulletin® Version 3.7.0
Copyright ©2000 - 2018, Jelsoft Enterprises Ltd.
ActiveMSers